Disclosures for "RGX-202, An Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Phase I/II Clinical Data "
-
Dr. Veerapandiyan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen, Novartis,Edgewise Therapeutics, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Inc., UCB Pharma, Catalyst, Entrada, Lupin, Percheron, ITF. Dr. Veerapandiyan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Veerapandiyan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Muscle and Nerve. The institution of Dr. Veerapandiyan has received research support from AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio, SolodBio and Sarepta Therapeutics. Dr. Veerapandiyan has received personal compensation in the range of $5,000-$9,999 for serving as a MD with PPMD, MDA.
-
The institution of Dr. Harper has received research support from Regenxbio. The institution of Dr. Harper has received research support from NS Pharma. The institution of Dr. Harper has received research support from Italafarmaco. The institution of Dr. Harper has received research support from Santhera. The institution of Dr. Harper has received research support from Dyne. The institution of Dr. Harper has received research support from Novartis. The institution of Dr. Harper has received research support from Fulcrum. The institution of Dr. Harper has received research support from MLBio. The institution of Dr. Harper has received research support from CDC. Dr. Harper has received personal compensation in the range of $5,000-$9,999 for serving as a Advisory Board with Sarepta . Dr. Harper has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Catalyst. Dr. Harper has a non-compensated relationship as a Clinic Director with MDA that is relevant to AAN interests or activities. Dr. Harper has a non-compensated relationship as a Clinic Director with PPMD that is relevant to AAN interests or activities.
-
Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AveXis. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AveXis. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catabasis. The institution of Dr. Iannaccone has received research support from AveXis. The institution of Dr. Iannaccone has received research support from Biogen. The institution of Dr. Iannaccone has received research support from Sarepta. The institution of Dr. Iannaccone has received research support from PTC Therapeutics. The institution of Dr. Iannaccone has received research support from FibroGen. The institution of Dr. Iannaccone has received research support from ReveraGen. The institution of Dr. Iannaccone has received research support from MDA. The institution of Dr. Iannaccone has received research support from PPMD. The institution of Dr. Iannaccone has received research support from NIH. Dr. Iannaccone has received personal compensation in the range of $0-$499 for serving as a grant reviewer with NIH.
-
Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenyx. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Audentes Therapeutics. Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Kuntz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Kuntz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Kuntz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. The institution of Dr. Kuntz has received research support from Argenx. The institution of Dr. Kuntz has received research support from Astellas. The institution of Dr. Kuntz has received research support from Biogen. The institution of Dr. Kuntz has received research support from Catalyst. The institution of Dr. Kuntz has received research support from Genentech. The institution of Dr. Kuntz has received research support from Scholar Rock. The institution of Dr. Kuntz has received research support from Regenx-Bio. The institution of Dr. Kuntz has received research support from Solid Biosciences. The institution of Dr. Kuntz has received research support from AMO. The institution of Dr. Kuntz has received research support from Novartis. The institution of Dr. Kuntz has received research support from BioHaven. Dr. Kuntz has received personal compensation in the range of $50,000-$99,999 for serving as a Sarepta Express post gene therapy advisor with Sarepta.
-
Dr. Tesi Rocha has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Tesi Rocha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Tesi Rocha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Tesi Rocha has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Tesi Rocha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenxbio. Dr. Tesi Rocha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ITALPHARMACO. Dr. Tesi Rocha has received personal compensation in the range of $500-$4,999 for serving as a Speaker at Symposium with Roche.
-
Nidal Boulos has received personal compensation for serving as an employee of REGENXBIO.
-
Catherine Wilson has received personal compensation for serving as an employee of REGENXBIO. Catherine Wilson has stock in REGENXBIO. Catherine Wilson has received personal compensation in the range of $100,000-$499,999 for serving as a Contractor with REGENXBIO.
-
Author has nothing to disclose
-
Michelle Gilmor has received personal compensation for serving as an employee of REGENXBIO. Michelle Gilmor has stock in REGENXBIO.
-
Ms. Curtiss has received personal compensation for serving as an employee of REGENXBIO. An immediate family member of Ms. Curtiss has received personal compensation for serving as an employee of Beacon Therapeutics . Ms. Curtiss has stock in REGENXBIO. An immediate family member of Ms. Curtiss has stock in Beacon Therapeutics.
-
Hiren Patel has received personal compensation for serving as an employee of Regenxbio. Hiren Patel has stock in Regenxbio.
-
Michele Fiscella has received personal compensation for serving as an employee of REGENXBIO. Michele Fiscella has stock in REGENXBIO. Michele Fiscella has received personal compensation in the range of $100,000-$499,999 for serving as a VP Translational & Bioanalytical Sciences with REGENXBIO.
-
Olivier Danos has received personal compensation for serving as an employee of regenxbio. Olivier Danos has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Coave Therapeutics. Olivier Danos has stock in regenxbio. Olivier Danos has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Pakola has received personal compensation for serving as an employee of Regenxbio.
-
Dr. Dastgir has received personal compensation for serving as an employee of Regenxbio. Dr. Dastgir has a non-compensated relationship as a Scientific Advisory Board with Team Titin that is relevant to AAN interests or activities. Dr. Dastgir has a non-compensated relationship as a Scientific Advisory Board with Hannah's Hope Fund / Gengan Therapeutics that is relevant to AAN interests or activities.